HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Terry Dex Selected Research

lixisenatide

12/2023Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus.
8/2023Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi: A Patient-Level Simulation Study.
1/2022Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes.
2/2019A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide.
1/2019Impact of lixisenatide dose range on clinical outcomes with fixed-ratio combination iGlarLixi in patients with type 2 diabetes.
1/2019Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world.
1/2019Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes.
11/2018Efficacy of iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements.
11/2018Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide alone.
1/2017Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Terry Dex Research Topics

Disease

21Type 2 Diabetes Mellitus (MODY)
12/2023 - 01/2017
5Hypoglycemia (Reactive Hypoglycemia)
01/2023 - 10/2018
5Weight Gain
01/2019 - 01/2017
2Body Weight (Weight, Body)
01/2019 - 01/2019
1Diabetes Mellitus
12/2023
1Pancreatitis
02/2019
1Neoplasms (Cancer)
02/2019
1Nausea
11/2018
1Vomiting
11/2018

Drug/Important Bio-Agent (IBA)

16Insulin (Novolin)FDA Link
12/2023 - 01/2017
10lixisenatideIBA
12/2023 - 01/2017
8Insulin Glargine (Lantus)FDA Link
08/2023 - 11/2018
5Glucagon-Like Peptide-1 ReceptorIBA
12/2023 - 01/2020
5Glucose (Dextrose)FDA LinkGeneric
01/2019 - 10/2018
4Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
02/2023 - 01/2019
2Metformin (Glucophage)FDA LinkGeneric
01/2022 - 01/2019
1insulin aspart protamine drug combination 30:70 insulin aspartIBA
09/2022
1Glucagon-Like Peptide-1 Receptor AgonistsIBA
11/2020
1Blood Glucose (Blood Sugar)IBA
01/2019
1Indicators and Reagents (Reagents)IBA
10/2018

Therapy/Procedure

8Therapeutics
12/2023 - 01/2020
4Glycemic Control
09/2022 - 10/2018
2Injections
01/2023 - 11/2020
1Aftercare (After-Treatment)
02/2023